Related Experiment Video

Updated: Jul 18, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Evaluation of Bacillus anthracis thymidine kinase as a potential target for the development of antibacterial

Cecilia Carnrot1, Susan R Vogel, Youngjoo Byun

  • 1Department of Molecular Biosciences, The Swedish University of Agricultural Biosciences, Biomedical Center, P.O. Box 575, S-751 23 Uppsala, Sweden.

Biological Chemistry
|November 30, 2006
PubMed

Insights

Researchers cloned and characterized Bacillus anthracis thymidine kinase (Ba-TK). This enzyme efficiently activates nucleoside analogs, showing potential for developing new anthrax treatments against drug-resistant strains.

Area of Science:

  • Biochemistry
  • Microbiology
  • Pharmacology

Background:

  • Bacillus anthracis poses a bioterrorism threat, necessitating novel antibiotics due to increasing multidrug resistance.
  • Thymidine kinase (TK) is crucial for activating nucleoside analog prodrugs, a strategy used in antiviral and anticancer therapies.
  • Identifying and characterizing B. anthracis TK (Ba-TK) is essential for designing targeted therapies.

Purpose of the Study:

  • To clone, express, and purify the thymidine kinase gene from Bacillus anthracis Sterne strain (Ba-TK).
  • To characterize the substrate specificity and kinetic properties of the purified Ba-TK enzyme.
  • To evaluate the potential of Ba-TK as a target for developing new anti-anthrax nucleoside analogs.

Main Methods:

  • Cloning and expression of the Ba-TK gene in E. coli.
  • Purification of the Ba-TK enzyme using standard biochemical techniques.
  • Enzyme kinetics assays to determine substrate specificity and kinetic parameters (Km, Vmax).
  • Size exclusion chromatography to assess the oligomeric state of Ba-TK.
  • In vitro growth inhibition assays using pyrimidine analogs.

Main Results:

  • Ba-TK efficiently phosphorylated pyrimidine nucleosides using natural nucleoside triphosphates as phosphate donors.
  • Size exclusion chromatography indicated Ba-TK exists as a dimer.
  • Thymidine was the most efficient substrate (Km = 0.6 microM), with deoxyuridine also showing significant activity (Km = 4.2 microM).
  • Pyrimidine analogs with modifications at the 5-position were more effective than those modified at the 3' or N3 positions.
  • Deoxyuridine analogs demonstrated potent inhibition of B. anthracis growth in vitro.

Conclusions:

  • The characterized Ba-TK enzyme is a promising target for developing novel nucleoside analog-based therapies against Bacillus anthracis.
  • The substrate specificity data provides a foundation for designing potent and selective anti-anthrax agents.
  • Further development of deoxyuridine analogs targeting Ba-TK could lead to effective treatments for anthrax, particularly against resistant strains.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...